Novartis (NVS) said that the US Food and Drug Administration has approved Cosentyx (secukinumab) to treat moderate to severe hidradenitis suppurativa in adults. Cosentyx is the only FDA-approved fully human biologic that directly inhibits interleukin-17A (IL-17A), a cytokine believed to be involved in the inflammation of hidradenitis suppurativa.
NICE recommends Novartis Cosentyx® (secukinumab) as the first biologic treatment for hidradenitis suppurativa (HS) since 2016 • Hidradenitis suppurativa (HS) is a painful, chronic and progressive inflammatory skin disease with over 50% of people reporting a mental health impact1,2 &bu.